Bank of Montreal Can Buys 20,240 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bank of Montreal Can increased its stake in Edwards Lifesciences Co. (NYSE:EW) by 1.7% during the second quarter, Holdings Channel reports. The firm owned 1,227,199 shares of the medical research company’s stock after acquiring an additional 20,240 shares during the period. Bank of Montreal Can’s holdings in Edwards Lifesciences were worth $112,706,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of EW. 9258 Wealth Management LLC increased its position in shares of Edwards Lifesciences by 24.8% in the fourth quarter. 9258 Wealth Management LLC now owns 10,529 shares of the medical research company’s stock worth $803,000 after purchasing an additional 2,093 shares during the period. Gryphon Financial Partners LLC grew its position in Edwards Lifesciences by 35.7% in the fourth quarter. Gryphon Financial Partners LLC now owns 6,454 shares of the medical research company’s stock valued at $492,000 after acquiring an additional 1,698 shares during the last quarter. Commerce Bank grew its position in Edwards Lifesciences by 0.6% in the fourth quarter. Commerce Bank now owns 37,938 shares of the medical research company’s stock valued at $2,893,000 after acquiring an additional 216 shares during the last quarter. Orion Portfolio Solutions LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at about $3,182,000. Finally, Congress Wealth Management LLC DE grew its position in Edwards Lifesciences by 16.3% in the fourth quarter. Congress Wealth Management LLC DE now owns 7,650 shares of the medical research company’s stock valued at $583,000 after acquiring an additional 1,070 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on EW shares. UBS Group decreased their target price on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 10th. Citigroup lifted their target price on Edwards Lifesciences from $105.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Piper Sandler decreased their target price on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. Finally, Wells Fargo & Company decreased their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $79.82.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,250 shares of company stock valued at $1,218,138. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $66.34 on Wednesday. The stock’s 50 day moving average is $69.02 and its 200 day moving average is $82.43. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The firm has a market cap of $39.98 billion, a P/E ratio of 28.59, a P/E/G ratio of 2.85 and a beta of 1.13. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same period in the previous year, the firm earned $0.66 earnings per share. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.7 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.